MX2021004487A - Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. - Google Patents

Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.

Info

Publication number
MX2021004487A
MX2021004487A MX2021004487A MX2021004487A MX2021004487A MX 2021004487 A MX2021004487 A MX 2021004487A MX 2021004487 A MX2021004487 A MX 2021004487A MX 2021004487 A MX2021004487 A MX 2021004487A MX 2021004487 A MX2021004487 A MX 2021004487A
Authority
MX
Mexico
Prior art keywords
pyrido
pyrimidin
formulation
derivatives
making
Prior art date
Application number
MX2021004487A
Other languages
English (en)
Inventor
Frank Stowasser
Peter Kuehl
Roland Meier
Urs Schwitter
Paepe Anne De
Juergen Thun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021004487A publication Critical patent/MX2021004487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de la 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2 -b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona útil como compuestos farmacéuticamente activos.
MX2021004487A 2018-10-19 2019-10-18 Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. MX2021004487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18201564 2018-10-19
PCT/EP2019/078313 WO2020079203A1 (en) 2018-10-19 2019-10-18 New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making

Publications (1)

Publication Number Publication Date
MX2021004487A true MX2021004487A (es) 2021-06-04

Family

ID=63965159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004487A MX2021004487A (es) 2018-10-19 2019-10-18 Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.

Country Status (12)

Country Link
US (1) US20210403487A1 (es)
EP (1) EP3867256A1 (es)
JP (2) JP2022505098A (es)
KR (1) KR20210079317A (es)
CN (1) CN113039188A (es)
AU (3) AU2019361273A1 (es)
BR (1) BR112021007200A2 (es)
CA (1) CA3116458C (es)
IL (1) IL281924A (es)
MX (1) MX2021004487A (es)
TW (1) TW202035411A (es)
WO (1) WO2020079203A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
CN114028351A (zh) * 2021-11-23 2022-02-11 莱默(北京)药业科技有限公司 一种利司扑兰冻干口崩片及制备方法
WO2024003798A1 (en) * 2022-06-29 2024-01-04 Biophore India Pharmaceuticals Pvt. Ltd. A novel process for the preparation of 7 (4, 7- diazaspiro [2.5] octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b] pyrid azin-6- yl) pyrido-4h-[1,2-a] pyrimidin-4-one with novel intermediates
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US9474047B2 (en) 2013-11-13 2016-10-18 Motorola Solutions, Inc. Apparatus and method for dynamically selecting unicast or broadcast resources for a push-to-talk call
SI3663296T1 (sl) 2014-05-15 2023-08-31 F. Hoffmann-La Roche Ag Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije
CA3002494C (en) * 2015-11-12 2021-01-12 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
JP7075484B2 (ja) * 2017-09-22 2022-05-25 エフ．ホフマン－ラ ロシュ アーゲー ７－（４，７－ジアザスピロ［２．５］オクタン－７－イル）－２－（２，８－ジメチルイミダゾ［１，２－ｂ］ピリダジン－６－イル）ピリド［１，２－ａ］ピリミジン－４－オン誘導体の製造方法

Also Published As

Publication number Publication date
TW202035411A (zh) 2020-10-01
IL281924A (en) 2021-05-31
JP2022505098A (ja) 2022-01-14
WO2020079203A1 (en) 2020-04-23
JP2023126944A (ja) 2023-09-12
CN113039188A (zh) 2021-06-25
EP3867256A1 (en) 2021-08-25
BR112021007200A2 (pt) 2021-08-10
AU2019361273A1 (en) 2021-05-06
CA3116458C (en) 2023-12-12
CA3116458A1 (en) 2020-04-23
AU2022215189B2 (en) 2023-11-09
KR20210079317A (ko) 2021-06-29
AU2022215189A1 (en) 2022-09-01
US20210403487A1 (en) 2021-12-30
AU2023254978A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
WO2013192556A3 (en) Salt crystals
MX2010006212A (es) Compuestos organicos.
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12018500944A1 (en) [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
MX2022004474A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
TWI800696B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EP3765462A4 (en) SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE AND IMIDAZO [1, 2-B] PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
MX2021014674A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
HK1154574A1 (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
IL243269B (en) Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts.
EP4072548A4 (en) COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZINE-1-YL)PYRAZOLO[ 1,5-A]PYRIMIDINE ANALOGUES AS INHIBITORS BY KRAS
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
MX2023010761A (es) Proceso para preparar risdiplam.
AU2018256494A1 (en) Method for the preparation of (1,2,4)-triazolo(4,3-A)pyridines
EP4118082A4 (en) PYRIDO[2,3-D PYRIMIDIN-7(8H)-ONE AS CDK INHIBITORS
MX2016005173A (es) Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico.
WO2023034965A3 (en) Co-crystals
WO2023147603A3 (en) Salt crystals